Eyal Rubin, who served as Chief Financial Officer and Executive Vice President of Nasus Pharma Ltd, filed a statement of changes in beneficial ownership on September 21, 2026, reporting his departure from both roles effective September 18, 2026.

Key Highlights

  • Departure effective date: Eyal Rubin ceased serving as Chief Financial Officer and Executive Vice President of Nasus Pharma Ltd on September 18, 2026.
  • Filing date: The ownership statement was signed and filed on September 21, 2026.
  • Reporting obligation ended: According to the filing, Rubin is "no longer subject to the reporting obligations under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to the Issuer."
  • No securities transactions reported: Neither Table I (non-derivative securities) nor Table II (derivative securities) contains any transaction entries.
  • Exchange and ticker: Nasus Pharma Ltd is listed under the ticker NSRX, as stated in the filing's issuer field.

Eyal Rubin Departs Nasus Pharma as CFO and Executive Vice President

According to the filing, Eyal Rubin submitted what is described as an "Exit Form 4" solely to report that he ceased serving as Chief Financial Officer and Executive Vice President of Nasus Pharma Ltd (NYSE:NSRX), effective September 18, 2026. The filing indicates no securities were acquired or disposed of in connection with this event, and both Table I and Table II contain no reported transactions.

The filing states that Rubin, whose address is listed as Tel-Aviv-Yafo, Israel, filed the form in his capacity as "One Reporting Person." His listed roles at the time of departure were Chief Financial Officer and Executive Vice President, and the filing confirms he held the "Officer" and "Other" designations in relation to the issuer. Nasus Pharma Ltd is a pharmaceutical company trading under the ticker NSRX.

The filing's remarks section states verbatim that the form "has been filed solely to report that Reporting Person ceased to serve as the Chief Financial Officer and Executive Vice President of Nasus Pharma Ltd." No amendment date is indicated, and the date of the earliest transaction is listed as September 18, 2026, corresponding to the effective date of his departure from the company's executive leadership.

What Was Disclosed

The filing discloses that Eyal Rubin stepped down as Chief Financial Officer and Executive Vice President of Nasus Pharma Ltd on September 18, 2026, and is no longer subject to Section 16 reporting obligations with respect to the issuer. No securities transactions were reported.